...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>ANZ journal of surgery. >Male breast cancer: a Singapore perspective
【24h】

Male breast cancer: a Singapore perspective

机译：Male breast cancer: a Singapore perspective

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相关主题

摘要

Abstract Introduction Male breast cancer (MBC) is rare, representing <1% of all breast cancers. Treatment recommendations have been extrapolated from trial data of female breast cancer patients. This study aims to report our institutional experience of MBC across a 20?year period, analyse the survival outcome and prognosis of this group against female breast cancer patients treated at the same centre. Methods Clinical, histopathological, treatment and survival data of male and female breast cancer patients treated between Jan 1999 and July 2019 at Singapore General Hospital and National Cancer Centre Singapore were identified and analysed. Results Fifty‐seven male patients were identified. The median age at diagnosis was 63?years. Majority had invasive ductal carcinoma (86%) and presented at an early disease stage: 70.2% presented as Tis/T1/T2 and 49.1% had no axillary nodal involvement. 84.2% had a simple mastectomy with either a sentinel lymph node biopsy or axillary clearance. The median follow up was 5.69?years for males and 5.83?years for females. The median survival was 11.86?years for males and 16.3?years for females. At 5?years, overall survival (OS) was 69.9% (52.3–82.1%) and disease free survival (DFS) was 62.9% (44.9–76.5%) for males compared with OS 83.8% (83.21–84.39%) and DFS 74.5% (73.91–75.09%) for females. Conclusion MBC remains understudied. Our institutional data indicates that good long term survival in South‐East Asian patients can be achieved with treatment protocols that are similar to female breast cancer. More prospective studies are required.

著录项

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号